Skip to main content
OpenTrials
Completed

NCT Number: NCT06333977

A Study of LC542019 in Healthy Subjects and Subjects With T2DM

to assess the safety, tolerability, Pharmacokinetics and Pharmacodynamics in healthy subjects and subjects with type 2 diabetes (T2DM).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

PPD Development, LP (PPD Clinical Research Unit, Las Vegas)

Las Vegas, Nevada, 89113, United States

About this study

The study will be conducted in 2 parts:

Part 1 (Single Ascending Dose) This part will include 6 sequential dose cohorts (S1-S6).

Part 2 (Multiple Ascending Dose) This part will include 5 sequential dose cohorts (M1-M5). Cohorts M1-M4 will enroll healthy subjects. Cohort M5 will enroll subjects with T2DM.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

For healthy subjects:

Inclusion criteria

  • Adults ≥ 18 to ≤ 55 years.
  • Body mass index (BMI) ≥18.5 to ≤ 30.0 kg/m2
  • Female subjects must be non-pregnant and non-lactating. Females of childbearing potential must use at least two of the medically accepted contraceptive methods, table at least 4 weeks prior to the screening.
  • Ability to provide written informed consent.

Exclusion criteria

  • History of or current diagnosis of Diabetes Mellitus Type 1 or Diabetes Mellitus Type 2
  • History of or current significant diagnosis of cardiovascular, respiratory, hepatic, renal, gastrointestinal endocrine, hematological, or neurological disorders or abnormalities, or other major systemic disease
  • History of or presence of clinically significant ECG findings
  • History of or acute significant gastrointestinal disorder

For T2DM subjects:

Inclusion criteria

  • Adults ≥ 18 to ≤ 70 years.
  • Body mass index (BMI) ≥18.5 to ≤ 35.0 kg/m2 with stable body weight by history for 3 months
  • Subjects with T2DM > 6 months, on stable therapy with metformin monotherapy.
  • Female subjects must be non-pregnant and non-lactating. Females of childbearing potential must use at least two of the medically accepted contraceptive methods, table at least 4 weeks prior to the screening.
  • Ability to provide written informed consent.

Exclusion criteria

  • History of or current diagnosis of Diabetes Mellitus Type 1
  • A subject who has acute proliferative retinopathy or maculopathy, severe gastroparesis, and/or severe neuropathy, especially autonomic neuropathy
  • Recurrent major hypoglycemia or hypoglycemic unawareness or recent ketoacidosis
  • Current use of any prescribed or non-prescribed drugs (other than current treatment for diabetes mellitus or birth control methods)

Treatment and study plan

LC542019

Drug

oral dose, once daily

Placebo

Drug

matching placebo

Primary outcomes

  1. Incidence, severity of adverse events

    Time frame: up to 4 weeks

Secondary outcomes

  1. Maximum Concentration (Cmax) in Plasma

    Time frame: up to 4 weeks

  2. Renal Clearance (CLR) in urine

    Time frame: up to 2 weeks

Other outcomes

  1. Cardiodynamic evaluation

    Time frame: up to 4 weeks

    concentration-QTc analysis

  2. Fasting Plasma Glucose

    Time frame: up to 4 weeks

  3. HbA1c

    Time frame: up to 4 weeks

Sponsors and collaborators

Lead sponsor

LG Chem

Industry

Registry information

Official study title

A First in Human, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LC542019 in Healthy Subjects and Subjects With T2DM

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Mar 27, 2024
Registry last updated
Mar 27, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.